Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching non-steroidal to steroidal aromatase inhibitor in adjuvant early breast cancer
2009-010786-22Phase 3Active
- Sponsor
- Innovative Sensor Technology IST AG
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of exemestane, anastrozole and letrozole in breast cancer (2 arms), sponsored by Innovative Sensor Technology IST AG. Primary endpoint: Disease-free survival. Started Mar 2009; status: active.
02
Drugs
exemestaneanastrozoleletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-010786-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010786-22.